Skip to main content
Erschienen in: Current Cardiology Reports 5/2010

01.09.2010

The Effect of Device Advisories on Implantable Cardioverter-defibrillator Therapy

verfasst von: Mitesh S. Amin, Kenneth A. Ellenbogen

Erschienen in: Current Cardiology Reports | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Implantable cardioverter-defibrillators have been shown to improve survival by terminating life-threatening ventricular tachyarrhythmias. As the devices have become more complex, there has been an increase in the incidence of device and lead malfunction. The device manufacturers issue advisories and recalls to alert physicians of the potential for malfunction. When patients are faced with a recalled device or lead, the initial question is whether or not to replace it. A rational approach to evaluating these patients and the associated advisory can help gauge the competing risks of elective device removal or extraction versus keeping the device in place. It is important to keep in mind that the risks of replacing devices or extracting leads are not insignificant and may outweigh the risks of death from malfunction. Despite the increasing number of advisories and attention to device and lead failure, the overall reliability and efficacy of these devices for appropriate patients remains high. In general, patients should be counseled prior to implant of the potential for device and lead malfunction, and careful consideration must be employed when decisions are made to replace generators or extract leads.
Literatur
1.
Zurück zum Zitat • Lee DS, Krahn AD, Healey JS, et al.: Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010, 55:774–782. This is a recent study examining predictors of complications with defibrillator implantations. • Lee DS, Krahn AD, Healey JS, et al.: Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010, 55:774–782. This is a recent study examining predictors of complications with defibrillator implantations.
2.
Zurück zum Zitat Carlson MD, Wilkoff BL, Maisel WH, et al.: Recommendations from the Heart Rhythm Society task force on device performance policies and guidelines. Heart Rhythm 2006, 3:1250–1273.CrossRefPubMed Carlson MD, Wilkoff BL, Maisel WH, et al.: Recommendations from the Heart Rhythm Society task force on device performance policies and guidelines. Heart Rhythm 2006, 3:1250–1273.CrossRefPubMed
3.
Zurück zum Zitat Maisel WH: Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions. JAMA 2005, 294:955–958.CrossRefPubMed Maisel WH: Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions. JAMA 2005, 294:955–958.CrossRefPubMed
4.
Zurück zum Zitat Maisel WH, Moynahan M, Zuckerman BD, et al.: Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006, 295:1901–1906.CrossRefPubMed Maisel WH, Moynahan M, Zuckerman BD, et al.: Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006, 295:1901–1906.CrossRefPubMed
5.
Zurück zum Zitat Gould PA, Krahn AD; Canadian Heart Rhythm Society Working Group on Device Advisories: Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006, 295:1907–1911.CrossRefPubMed Gould PA, Krahn AD; Canadian Heart Rhythm Society Working Group on Device Advisories: Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006, 295:1907–1911.CrossRefPubMed
6.
Zurück zum Zitat • Priori SG, Auricchio A, Nisam S, Yong P: To replace or not to replace: a systematic approach to respond to device advisories. J Cardiovasc Electrophysiol 2009, 20:164–170. This is a mathematical model constructed to calculate a “number needed to replace” to assess whether or not device replacement is preferred. • Priori SG, Auricchio A, Nisam S, Yong P: To replace or not to replace: a systematic approach to respond to device advisories. J Cardiovasc Electrophysiol 2009, 20:164–170. This is a mathematical model constructed to calculate a “number needed to replace” to assess whether or not device replacement is preferred.
7.
Zurück zum Zitat Varma N: Remote monitoring for advisories: automatic early detection of silent lead failure. Pacing Clin Electrophysiol 2009, 32:525–527.CrossRefPubMed Varma N: Remote monitoring for advisories: automatic early detection of silent lead failure. Pacing Clin Electrophysiol 2009, 32:525–527.CrossRefPubMed
8.
Zurück zum Zitat •• Haqqani HM, Mond HG: The implantable cardioverter-defibrillator lead: principles, progress, and promises. Pacing Clin Electrophysiol 2009, 32:1336–1353. This is a review of the evolution of ICD leads and examination of the problems with ICD lead failures. •• Haqqani HM, Mond HG: The implantable cardioverter-defibrillator lead: principles, progress, and promises. Pacing Clin Electrophysiol 2009, 32:1336–1353. This is a review of the evolution of ICD leads and examination of the problems with ICD lead failures.
9.
Zurück zum Zitat •• Smith MC, Love CJ: Extraction of transvenous pacing and ICD leads. Pacing Clin Electrophysiol 2008, 31:736–752. This systematic review summarizes tools and techniques that can be used to safely extract leads, while discussing problems encountered with the majority of failures. •• Smith MC, Love CJ: Extraction of transvenous pacing and ICD leads. Pacing Clin Electrophysiol 2008, 31:736–752. This systematic review summarizes tools and techniques that can be used to safely extract leads, while discussing problems encountered with the majority of failures.
10.
Zurück zum Zitat Schoenfeld MH, Reynolds DW: Sophisticated remote implantable cardioverter-defibrillator follow-up: a status report. Pacing Clin Electrophysiol 2005, 28:235–240.CrossRefPubMed Schoenfeld MH, Reynolds DW: Sophisticated remote implantable cardioverter-defibrillator follow-up: a status report. Pacing Clin Electrophysiol 2005, 28:235–240.CrossRefPubMed
11.
Zurück zum Zitat Kay GN, Brinker JA, Kawanishi DT, et al.: Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation 1999, 100:2344–2352.PubMed Kay GN, Brinker JA, Kawanishi DT, et al.: Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation 1999, 100:2344–2352.PubMed
12.
Zurück zum Zitat Maisel WH: Physician management of pacemaker and implantable cardioverter-defibrillator advisories. Pacing Clin Electrophysiol 2004, 27:437–442.CrossRefPubMed Maisel WH: Physician management of pacemaker and implantable cardioverter-defibrillator advisories. Pacing Clin Electrophysiol 2004, 27:437–442.CrossRefPubMed
13.
Zurück zum Zitat • Amin MS, Wood MA, Shepard RK, et al.: Clinical judgment versus decision analysis for managing device advisories. Pacing Clin Electrophysiol 2008, 31:1236–1240. This is a single-center retrospective review comparing physician practices versus decision analysis for handling devices under advisory. • Amin MS, Wood MA, Shepard RK, et al.: Clinical judgment versus decision analysis for managing device advisories. Pacing Clin Electrophysiol 2008, 31:1236–1240. This is a single-center retrospective review comparing physician practices versus decision analysis for handling devices under advisory.
14.
Zurück zum Zitat •• Gould PA, Gula LJ, Champagne J, et al.: Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm 2008, 5:1675–1681. This is a detailed account of the Canadian experience with managing ICD advisories, specifically detailing complications endured during elective replacement. •• Gould PA, Gula LJ, Champagne J, et al.: Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm 2008, 5:1675–1681. This is a detailed account of the Canadian experience with managing ICD advisories, specifically detailing complications endured during elective replacement.
15.
Zurück zum Zitat Kapa S, Hyberger L, Rea RF, Hayes DL: Complication risk with pulse generator change: implications when reacting to a device advisory or recall. Pacing Clin Electrophysiol 2007, 30:730–733.CrossRefPubMed Kapa S, Hyberger L, Rea RF, Hayes DL: Complication risk with pulse generator change: implications when reacting to a device advisory or recall. Pacing Clin Electrophysiol 2007, 30:730–733.CrossRefPubMed
16.
Zurück zum Zitat Costea A, Rardon DP, Padanilam BJ, et al.: Complications associated with generator replacement in response to device advisories. J Cardiovasc Electrophysiol 2008, 19:266–269.CrossRefPubMed Costea A, Rardon DP, Padanilam BJ, et al.: Complications associated with generator replacement in response to device advisories. J Cardiovasc Electrophysiol 2008, 19:266–269.CrossRefPubMed
17.
Zurück zum Zitat • Xu W, Moore HJ, Karasik PE, et al.: Management strategies when implanted cardioverter defibrillator leads fail: survey findings. Pacing Clin Electrophysiol 2009, 32:1130–1141. This is a summary of findings from a survey of management strategies for lead failures. • Xu W, Moore HJ, Karasik PE, et al.: Management strategies when implanted cardioverter defibrillator leads fail: survey findings. Pacing Clin Electrophysiol 2009, 32:1130–1141. This is a summary of findings from a survey of management strategies for lead failures.
18.
Zurück zum Zitat Amin MS, Matchar DB, Wood MA, Ellenbogen KA: Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model. JAMA 2006, 296:412–420.CrossRefPubMed Amin MS, Matchar DB, Wood MA, Ellenbogen KA: Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model. JAMA 2006, 296:412–420.CrossRefPubMed
19.
Zurück zum Zitat • Gula LJ, Massel D, Krahn AD, et al.: Survival rates as a guide to implanted cardioverter-defibrillator replacement strategies for device recalls—adding statistical insight to clinical intuition. Am Heart J 2007, 153:253–259. This is another similar Markov model with a slightly different methodology. • Gula LJ, Massel D, Krahn AD, et al.: Survival rates as a guide to implanted cardioverter-defibrillator replacement strategies for device recalls—adding statistical insight to clinical intuition. Am Heart J 2007, 153:253–259. This is another similar Markov model with a slightly different methodology.
20.
Zurück zum Zitat •• Wazni O, Epstein LM, Carrillo RG, et al.: Lead extraction in the contemporary setting: the LExICon study, an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol 2010, 55:579–586. This is a large multicenter study highlighting the risks associated with lead extraction. •• Wazni O, Epstein LM, Carrillo RG, et al.: Lead extraction in the contemporary setting: the LExICon study, an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol 2010, 55:579–586. This is a large multicenter study highlighting the risks associated with lead extraction.
21.
Zurück zum Zitat Wilkoff BL, Byrd CL, Love CJ, et al.: Trends in intravascular lead extraction: analysis of data from 5339 procedures in 10 years. XIth World Symposium on Cardiac Pacing and Electrophysiology, Berlin. Pacing Clin Electrophysiol 1999, 22(Pt II):A207. Wilkoff BL, Byrd CL, Love CJ, et al.: Trends in intravascular lead extraction: analysis of data from 5339 procedures in 10 years. XIth World Symposium on Cardiac Pacing and Electrophysiology, Berlin. Pacing Clin Electrophysiol 1999, 22(Pt II):A207.
22.
Zurück zum Zitat Hauser RG, Katsiyiannis WT, Gornick CC, et al.: Deaths and cardiovascular injuries due to device assisted implantable cardioverter-defibrillator and pacemaker lead extraction. Europace 2010, 12:395–401.CrossRefPubMed Hauser RG, Katsiyiannis WT, Gornick CC, et al.: Deaths and cardiovascular injuries due to device assisted implantable cardioverter-defibrillator and pacemaker lead extraction. Europace 2010, 12:395–401.CrossRefPubMed
23.
Zurück zum Zitat Birnie DH, Sears SF, Green MS, et al.: No long-term psychological morbidity living with an implantable cardioverter defibrillator under advisory: the Medtronic Marquis experience. Europace 2009, 11:26–30.CrossRefPubMed Birnie DH, Sears SF, Green MS, et al.: No long-term psychological morbidity living with an implantable cardioverter defibrillator under advisory: the Medtronic Marquis experience. Europace 2009, 11:26–30.CrossRefPubMed
24.
Zurück zum Zitat Gibson DP, Kuntz KK, Levenson JL, Ellenbogen KA: Decision-making, emotional distress, and quality of life in patients affected by the recall of their implantable cardioverter defibrillator. Europace 2008, 10:540–544.CrossRefPubMed Gibson DP, Kuntz KK, Levenson JL, Ellenbogen KA: Decision-making, emotional distress, and quality of life in patients affected by the recall of their implantable cardioverter defibrillator. Europace 2008, 10:540–544.CrossRefPubMed
Metadaten
Titel
The Effect of Device Advisories on Implantable Cardioverter-defibrillator Therapy
verfasst von
Mitesh S. Amin
Kenneth A. Ellenbogen
Publikationsdatum
01.09.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 5/2010
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-010-0124-7

Weitere Artikel der Ausgabe 5/2010

Current Cardiology Reports 5/2010 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.